MedTrace Logo

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

NCT00532311 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 411

Last updated 2016-06-22

No results posted yet for this study

Summary

The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with statins on cholesterol levels in subjects with hypercholesterolemia

Conditions

Interventions

DRUG

Lapaquistat acetate and stable statin therapy

Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.

DRUG

Stable statin therapy

Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00532311 on ClinicalTrials.gov